Navigation Links
Drop in testosterone tied to prostate cancer recurrence
Date:10/28/2012

BOSTON, MA (October 28, 2012)Men whose testosterone drops following radiation therapy for prostate cancer are more likely to experience a change in PSA levels that signals their cancer has returned, according to new research from Fox Chase Cancer Center. The findings will be presented on October 29 at the American Society for Radiation Oncology's 54th Annual Meeting.

Specifically, men whose testosterone fell following various forms of radiation therapy were more likely to experience an increase in prostate-specific antigen (PSA)often the first indication the cancer has recurred.

"The men who had a decrease in testosterone also appear to be the men more likely to see an increase in PSA after treatment," says study author Jeffrey Martin, MD, resident physician in the Department of Radiation Oncology at Fox Chase.

In theory, doctors may one day be able to use testosterone levels to guide treatment decisions, says Martin. "For men with a decrease in testosterone, doctors might intervene earlier with other medications, or follow their PSA more closely than they would otherwise, to spot recurrences at an earlier time."

Martin and his colleagues decided to conduct the study because there is limited information regarding testosterone levels after radiation treatment and what it means for prognosis. To investigate whether a decrease in testosterone has any clinical effects, Martin and his colleagues reviewed medical records from nearly 260 men who received radiation therapy for prostate cancer between 2002 and 2008. The men were treated with either brachytherapy, in which doctors insert radioactive seeds in the prostate, or intensity modulated radiation therapy (IMRT), in which an external beam of radiation is directed at the prostate.

The researchers found that testosterone levels tended to decrease following both forms of radiation therapy. And men who experienced a post-radiation drop in testosterone particularly a significant dropwere more likely to see their PSA levels rise during the follow-up period.

Still, an increase in PSAknown as biochemical failurewas relatively rare, the authors found. "Only 4% of patients with low-risk prostate cancer had biochemical failure at five years," says Martin.

Even though researchers have seen testosterone decrease following another form of radiation, these latest findings are still somewhat surprising, says Martin, because testosterone is believed to drive prostate cancer. In fact, some patients with advanced forms are prescribed hormone therapy that attempts to knock down testosterone.

"Seeing that a drop in testosterone is tied to recurrence is kind of a surprising result," says Martin. "We don't necessarily know what this means yet. I think the relationship between testosterone levels following radiation therapy and prognosis needs more study, and until then it's premature to say this is something patients should ask their doctors about."

This was a small study that needs to be validated in a larger group of men before doctors begin basing their predictions of recurrence on patients' testosterone levels, he cautions. "I think the link between testosterone and PSA needs more study, in a larger set of patients."


'/>"/>
Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Genetic markers for testosterone and estrogen level regulation identified
2. BUSM researchers identify genetic markers for testosterone, estrogen level regulation
3. Weight Loss May Increase Testosterone Levels
4. Long-term testosterone treatment for men results in reduced weight and waist size
5. Declining testosterone levels in men not part of normal aging, study finds
6. Proposed testosterone testing of some female olympians challenged by Stanford scientists
7. Can Testosterone Therapy Help Obese Men Lose Weight?
8. Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
9. First web-based prostate cancer database launches
10. Lab Contamination Behind Debunked Link Between Virus, Prostate Cancer
11. Researchers reveal underlying mechanism of powerful chemotherapy for prostate cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Dave Newberry, ... Pediatric Interim Care Center (PICC) annual fundraiser luncheon on Friday, May 20. “We ... helps the smallest victims of drug abuse,” said Newberry. , PICC is a local ...
(Date:5/2/2016)... ... May 03, 2016 , ... RNK Products, Inc. ... stethoscope software that enables the stethoscope stream to go over the video conferencing ... RNK’s flagship PCP-USB stethoscope. , Remote auscultation involves two software elements on the ...
(Date:5/2/2016)... ... 02, 2016 , ... ProElectric Cartoon is a package of 30 hand-drawn electrifying ... a variety of electric styles including zap, sizzles, and more. Easily alter the highlights, ... three dimensional rotation, and much more. ProElectric Cartoon’s simplistic style makes it the perfect ...
(Date:5/2/2016)... ... ... Pets bring laughter, joy and love into people’s homes without asking for ... which falls on the first full week of May. These seven days, May 1 ... recognize responsible pet ownership. Pet owners can live out these values by following action ...
(Date:5/2/2016)... ... May 02, 2016 , ... Eating Recovery Center’s ... eating, mood and anxiety disorders, has rebranded its eating disorder program under a new ... eating disorder treatment facility on May 16. , To celebrate, ERC Chicago will ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016  In the ... projected to shift from systems dependent on CRTs monitors ... types of modality CRT Medical monitors and will ... are a host of foreseeable benefits to this ... will existing modalities have to be replaced in ...
(Date:4/29/2016)... New Jersey , April 29, 2016 /PRNewswire/ ... Software Suite for Life Sciences, Product Development Capabilities ... Global Life Science Customer Base . ... solutions provider, today announced the acquisition of Skura ... a global leader in adaptive sales enablement technology ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology ... appointment of Dr. Alfredo Zurlo as Chief ... with many years clinical experience and a proven track ... role was at Mologen AG where he was Chief ... Dr. Zurlo held various positions at F Hoffmann La ...
Breaking Medicine Technology: